Skip to main content

Table 2 Concentration of eicosanoids and eosinophilic inflammation markers in chronic rhinosinusitis patients

From: Expression of eicosanoid receptors subtypes and eosinophilic inflammation: implication on chronic rhinosinusitis

 

Controls

CRS

CRS-NP

Kruskall Wallis-test

Eicosanoids

LTC4/D4/E4 (ng/ml)

1.16 (IQR: 0.85–1.68)

3.34 (IQR: 2.70–5.35)

7.24 (IQR: 4.65–12.40)

P < 0.01 §

LTB4 (ng/ml)

25.25 (IQR: 8.26–63.91)

21.95 (IQR: 9.40–31.90)

19.44 (IQR: 12.80–29.71)

N.S

PGE2 (ng/ml)

180.63 (IQR: 101.44–258.86)

199.83 (IQR: 59.10–223.52)

55.00 (IQR: 40.59–67.87)

p = 0.02 ¶

Eosinophilic inflammation markers

ECP (μg/L)

602.51 (IQR: 309.90–894.30)

2090.00 (IQR: 1437.60–5442.40)

11880.00 (IQR: 1862.70–17920.74)

p < 0.01 §

Sol-IL-5Rα protein (ng/ml)

20.62 (IQR: 15.77–26.43)

50.95 (IQR: 28.62–67.78)

175.24 (IQR: 37.11–309.67)

P < 0.05 §

sol-IL-5Rα mRNA (pg/μl)

14757.50 (IQR: 12493.97–23015.35)

159065.30 (IQR: 45909.00–185796.90)

458449.55 (IQR: 267447.00–796387.30)

p = 0.02 §

EG2 positive cells

1,00 (IQR: 1,00–1,15)

1,05 (IQR: 1,00–1,40)

2,10 (IQR: 1,90–2,25)

p < 0.01 ¶

  1. Results are expressed as median and interquartile ranges (IQR). §: p < 0.05 is due to differences between the three sample groups; (¶): p < 0.05 is due to differences in the levels of CRS-NP versus controls and CRS patients. N.S: No statistical differences, p value > 0.05. CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyp, Controls: healthy subjects.